Oncotarget

Research Papers:

SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis

Zhenghao Zhang, Shu Chen, Shuang Chen, Gang Chen, Rui Zhang, Jinhua Li and Jianhua Qu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:69916-69923. https://doi.org/10.18632/oncotarget.19455

Metrics: PDF 2034 views  |   HTML 2100 views  |   ?  


Abstract

Zhenghao Zhang1, Shu Chen2, Shuang Chen1, Gang Chen1, Rui Zhang1, Jinhua Li1 and Jianhua Qu1

1Centre of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

2Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

Correspondence to:

Jianhua Qu, email: [email protected]

Keywords: SF3B1, chronic lymphocytic leukemia, prognosis, survival, meta-analysis

Received: December 01, 2016     Accepted: May 27, 2017     Published: July 22, 2017

ABSTRACT

Recent studies suggest that SF3B1 might be related to poor prognosis in CLL, but the results remain controversial. This meta-analysis was performed to clarify the relationship between SF3B1 mutation and prognosis in patients with CLL. The relevant published reports were searched in PubMed, EMBASE, and Web of Science. A total of 13 articles were included in this meta-analysis as they met the inclusion and exclusion criteria. The hazard ratios (HRs) and corresponding 95% confidence intervals (95%CIs) for progression free survival (PFS) and/or overall survival (OS) were extracted from each eligible study. The pooled HR evaluating SF3B1 mutation on PFS was 1.81(95%CI 1.33-2.46, I2=78.9%, P<0.001) and on on OS was 2.57(95%CI 1.68-3.94, I2=79.3%, P<0.001) by random effects model. In conclusion, SF3B1 mutation was significantly associated with poor PFS and OS in CLL. It could be consider as a potential prognostic factor in patients with CLL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19455